BioPorto Diagnostics A/S is a Danish in-vitro diagnostic company that provides biomarkers, research antibodies and assays to scientists and clinicians worldwide. We use our antibody and assay expertise to transform novel research tools into clinically actionable assays that can make a difference in patients’ lives. Our flagship product, The NGAL Test™, aids in the rapid risk assessment of acute kidney injury (AKI) in critically ill patients by measuring the NGAL biomarker associated with renal tubular injury. AKI is common among hospitalized patients, affecting 1 in 5 adults and 1 in 4 children. It is often asymptomatic and can be difficult to identify. To learn more about this public health concern, visit https://bioporto.com/aki/. Designed to run on standard chemistry analyzers, The NGAL Test is CE marked and available for IVD use in the EU, Canada, Korea and Israel, and is for research use only in all other regions. BioPorto Diagnostics’ patented generic Rapid Assay Device (gRAD) is a platform technology that is designed to facilitate the fast and easy development of custom lateral flow assays. It has been used in a variety of research projects including to determine levels of NGAL, and to quantify levels of thrombomodulin in early sepsis. Currently, gRAD is also being investigated for potential COVID-19 applications. We also offer highly specific antibodies suitable for research into clinical conditions such as AKI, obesity, diabetes, innate immunity, allergy and infectious diseases. Headquartered in Hellerup, Denmark, BioPorto A/S is listed on the NASDAQ Copenhagen stock exchange. [CPH: BIOPOR] To learn more about our products and their availability in your country, please visit https://bioporto.com/products/. Posts are not intended for a U.S. audience. If you are from the United States, you are encouraged to visit https://www.linkedin.com/company/bioporto-diagnostics-inc-us/ Social Media Community Guidelines: https://bioporto.com/social-media/